In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial.
Subscribe to:
Post Comments (Atom)
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
Training artificial intelligence models on more diverse image and data sets can augment decision making, overcome knowledge gaps, and promot...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
No comments:
Post a Comment